Sociedad Americana de Hirudoterapia

Relationship between fibula free flap complications and dental implant outcomes: a retrospective cohort study

Research article published in Frontiers in oral health (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosAttia et al. · Frontiers in oral health, 2025

Abstract

OBJECTIVE: To clarify how fibula free flap (FFF) complications influence clinical and functional outcomes after implant-supported oral rehabilitation. MATERIALS AND METHODS: A single-center retrospective cohort of 29 patients (56.41 ± 12.74 years; 31% female, 69% male) who underwent segmental jaw resection, FFF reconstruction and subsequent implant placement (2002-2010) was analyzed. Demographic, oncologic, flap, implant-related and patient-centered functional variables were extracted; associations were tested with exact, rank and regression statistics (⍺ = 0.05). RESULT: Patients received 7.14 ± 3.06 implants each and 72% were restored with telescopic overdentures. Recipient-site wound-healing defects (WHD) occurred in 31% and were independently associated with multisegment osteotomies (p = 0.012) and longer operative time (p = 0.026); partial flap loss (PFL) was infrequent (6.9%). WHD reduced maximum inter-incisal opening (MIO) by 0.8 cm and PFL by 2.8 cm, both impairing contour ratings. Implant failure (0.59 ± 1.59) correlated with poorer speech intelligibility (p = 0.004) and lower aesthetic scores (p = 0.032). Nonetheless, 96% of patients spoke intelligibly (with or without concentration), 96% judged their dental aesthetic as good or excellent, and 75% consumed a normal diet. Ordinal regression confirmed the number of fibula segments as the sole predictor of contour (p = 0.001). CONCLUSIONS: FFF reconstruction permits dependable, implant-supported rehabilitation, but multisegment osteotomies and prolonged surgery heighten soft-tissue morbidity, which in turn constrains both MIO and appearance. Failed implants further degrade speech intelligibility and aesthetics. Long-term success therefore hinges on balancing the contour gains of complex osteotomies with flap vascular resilience while safeguarding implant stability.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Resumen

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Por qué esto importa para la hirudoterapia

Este estudio retrospectivo de cohorte de un solo centro de 29 pacientes rastreó cómo las complicaciones de la reconstrucción mandibular con injerto libre de fibula (FFF) afectaron la rehabilitación oral posterior con implantes, encontrando que las defectos de cicatrización en el sitio receptora ocurrieron en un 31% y estaban independientemente vinculados a osteotomías multisegmentarias y tiempo operatorio más largo, mientras que los implantes fallidos se correlacionaron con una peor inteligibilidad del habla y estética; no obstante, el 96% habló con inteligibilidad y juzgó la estética como buena o excelente. Para la hirudoterapia, la relevancia es contextual más que directa: la reconstrucción con injerto libre y microvascular es precisamente el escenario quirúrgico en el que se utilizan las sanguijuelas medicinales como terapia de salvamento para la congestión venosa, y este estudio subraya cómo la resiliencia vascular del injerto conduce al éxito a largo plazo. El resumen no estudia ni menciona la terapia con sanguijuelas, y con solo 29 pacientes en un solo centro los hallazgos son de nivel hipotético y no se pueden generalizar.

Citación

Relationship between fibula free flap complications and dental implant outcomes: a retrospective cohort study.

Attia et al. · Frontiers in oral health, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.